Peter Aichele

Principal Investigator

Institute for Immunodeficiency (IFI)
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg

Hermann Herder Str. 11
79104 Freiburg i. Brsg.

Current position

Group leader, Institute for Immunodeficiency, Medical Center – University of Freiburg

Academic training

1983 – 1990 Study of Biology in Freiburg and Zurich, Switzerland

Scientific qualifications

1991 – 1996 PhD Thesis in Experimental Immunology, University of Zurich, Switzerland (Supervisor: Prof. Hans Hengartner)

Postgraduate Positions

since 2019 Group leader, Institute for Immunodeficiency,
Medical Center - University of Freiburg
since 2012 Group leader, Institute for Immunology, Center for Microbiology and Hygiene, Medical Center - University of Freiburg
1998 – 2002 Research Fellow, Max-Planck-Institute for Infection Biology, Berlin
1996 – 1997 Postdoctorate, Department of Experimental Immunology, University Hospital Zurich, Switzerland

link to all publications from P. Aichele: Pubmed

Publications based on CRC1160 funding

Dettmer-Monaco V, Weißert K, Ammann S, Monaco G, Lei L, Gräßel L, Rhiel M, Rositzka J, Kaufmann MM, Geiger K, Andrieux G, Lao J, Thoulass G, Schell C, Boerries M, Illert AL, Cornu TI, Ehl S, Aichele P, Cathomen T. 2024. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. Jan;153(1):243-255.e14. doi: 10.1016/j.jaci.2023.08.003.

Raute K, Strietz J, Parigiani MA, Andrieux G, Thomas OS, Kistner KM, Zintchenko M, Aichele P, Hofmann M, Zhou H, Weber W, Boerries M, Swamy M, Maurer J, Minguet S. 2023. Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands. Cancer Immunol Res. 2023 May 4:OF1-OF20. doi: 10.1158/2326-6066.CIR-22-0296.

Kemna J, Gout E, Daniau L, Lao J, Weißert K, Ammann S, Kühn R, Richter M, Molenda C, Sporbert A, Zocholl D, Klopfleisch R, Lortat-Jacob H, Aichele P, Kammertoens T, Blankenstein T. 2023. IFNγ binding to extracellular matrix prevents fatal systemic toxicity. Nat Immunol. 24, 414–422.

Weissert, K., S. Ammann, T. Kogl, V. Dettmer-Monaco, C.  Schell, T. Cathomen, S. Ehl, and P. Aichele. 2022. Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH). EMBO Mol Med: e16085. doi: 10.15252/emmm.202216085.

Aichele P, Neumann-Haefelin C, Ehl S, Thimme R, Cathomen T, Boerries M, Hofmann M. 2022. Immunopathology caused by impaired CD8+ T-cell responses. Eur J Immunol. Jan 31. doi: 10.1002/eji.202149528. Online ahead of print.

Fixemer J, Hummel JF, Arnold F, Klose CSN, Hofherr A, Weissert K, Kögl T, Köttgen M, Arnold SJ, Aichele P, Tanriver Y. 2020. Eomes cannot replace its paralog T-bet during expansion and differentiation of CD8 effector T cells. PLoS Pathog. 16(9):e1008870. doi: 10.1371/journal.ppat.1008870.

Gather, R., P. Aichele, N. Goos, J. Rohr, H. Pircher, T. Kogl, R. Zeiser, H. Hengel, A. Schmitt-Graff, C. Weaver, and S. Ehl. 2020. Trigger-dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis. Eur J Immunol. doi: 10.1002/eji.201948123. [Epub ahead of print].

Dettmer, V., K. Bloom, M. Gross, K. Weissert, Aichele, S. Ehl, and T. Cathomen. 2019. Retroviral UNC13D gene transfer restores cytotoxic activity of T cells derived from familial hemophagocytic lymphohistiocytosis type 3 patients in vitro. Hum Gene Ther. 30(8): 975-984.

Rauch KS, Hils M, Menner AJ, Sigvardsson M, Minguet S, Aichele P, Schachtrup C, Schachtrup K. 2017. Regulatory T cells characterized by low Id3 expression are highly suppressive and accumulate during chronic infection. Oncotarget. 8(61): 102835-102851.

Gamez-Diaz, L., J. Neumann, F. Jager, M. Proietti, F. Felber, P. Soulas-Sprauel, L. Perruzza, F. Grassi, T. Kogl, Aichele, M. Kilimann, B. Grimbacher, and S. Jung. 2017. Immunological phenotype of the murine Lrba knockout. Immunol Cell Biol 95: 789-802.